This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Graymark, Orexigen: Volume Movers

BOSTON ( TheStreet) -- Graymark Healthcare (GRMH) was one of several stocks trading below $10 poised to move on above-average volume Thursday as shares surged on the announcement of an agreement between the company and Walgreen (WAG).

Graymark Healthcare said late Wednesday it will sell the assets of 18 ApothecaryRx pharmacies to Walgreen. Terms of the agreement were not disclosed, although the companies said the transaction is expected to close in the fourth quarter. Stanton Nelson, Chairman and CEO of Graymark, said the divestiture will help the company focus on its sleep apnea business.

Shares of Graymark Healthcare jumped by 25 cents, or 22.9%, to $1.34 in Wednesday's after-market session. The average daily share volume for Graymark is 9,000.

Elsewhere, Orexigen Therapeutics (OREX - Get Report) shares rallied by $1.02, or 22.2%, to $5.61 in the premarket session after the company entered into a partnership with Takeda Pharmaceutical to commercialize obesity drug Contrave in North America. Orexigen will receive an upfront cash payment of $50 mln from Takeda for exclusive marketing rights in the U.S., Mexico and Canada. Orexigen retains the right to co-promote with Takeda in the U.S. and will be eligible to receive regulatory and sales-based milestone payments of over $1 billion. The average daily share volume for Orexigen is 1.12 million.

TheStreet's Adam Feuerstein notes that Contrave is similar to Vivus' (VVUS) Qnexa in that "it's a two-drug combination designed to help patients lose weight." Feuerstein adds that "none of the large U.S.-based pharmaceutical companies have been willing to sign obesity drug deals."

Cardiome Pharma (CRME - Get Report) climbed by 81 cents, or 13.1%, to $7 in Wednesday's late trading session after the company and partner Merck (MRK - Get Report) received a marketing approval related to an intravenous formulation of their Brinavess brand vernakalant cardiovascular drug in the European Union, Iceland and Norway. The average daily share volume for Cardiome is 306,000.

K-Sea Transportation Partners (KSP) may trade on increased volume after the company said it would raise up to $100 million by selling about 18.4 million convertible preferred units to KA First Reserve. Proceeds from the preferred unit sale will be used to repay debt, the company said. K-Sea also amended its credit facility to reduce lenders' commitments to $115 million from $175 million.

In addition, K-Sea posted a fiscal fourth-quarter adjusted loss of 37 cents a share, which was wider than the 33-cent-a-share loss analysts had predicted, according to Thomson Reuters. Revenue in the quarter fell by 8% from a year ago to $66.7 million, although that was above the consensus target of $65.9 million.

On Tuesday, K-Sea postponed its fiscal fourth-quarter earnings conference call as the tugboat and barge fleet operator worked with its lenders to extend a waiver period that expired Tuesday. The average daily share volume for K-Sea Transportation is 88,000.

-- Written by Robert Holmes in Boston.

>To contact the writer of this article, click here: Robert Holmes.

>To follow Robert Holmes on Twitter, go to

>To submit a news tip, send an email to:
Disclosure: TheStreet's editorial policy prohibits staff editors, reporters and analysts from holding positions in any individual stocks.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
CRME $4.52 0.00%
MRK $55.74 -1.01%
OREX $0.47 2.53%
WAG $81.65 2.05%
AAPL $95.03 -2.90%


Chart of I:DJI
DOW 17,830.76 -210.79 -1.17%
S&P 500 2,075.81 -19.34 -0.92%
NASDAQ 4,805.2910 -57.85 -1.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs